CNBC Investing Club

Bausch Health's stock soars on solid quarterly results, but we have concerns about the recovery

A worker demonstrates a Bausch vial filling machine during the International Pharmaceutical Expo (Interphex) in New York, U.S., on Tuesday, March 21, 2017. Interphex is a pharmaceutical, biotechnology, and medical device development and manufacturing event offering access to new business trends and strategies. Photographer: Timothy Fadek/Bloomberg via Getty Images
Bloomberg | Bloomberg | Getty Images

Club holding Bausch Health Companies (BHC) on Thursday reported fourth-quarter results ahead of expectations, even as an ongoing patent dispute keeps us skeptical about the stock's ability to stage a sustained rebound.